

# New Jersey Based Optimal Therapeutics Announces the Signing of Licensing Agreement for the Trademarked Ingredient Nextrutine(R) in Their Phosoplex Joint Formulation

CEDAR GROVE, NJ /Send2Press Newswire/ – New Jersey based Optimal Therapeutics announces the signings of licensing agreements for trademarked ingredients in their Phosoplex Joint Formulation. BioCell Collagen II from BioCell Technology LLC and Nextrutine(R) from Next Pharmaceutical are exciting ingredient additions to an already potent joint health formula.

Company spokesperson Camille Westhoff states: “Phosoplex with the addition of these two key ingredients puts Optima Therapeutics at the forefront of joint health and pain relief. It’s great to be associated with a product like Phosoplex because it can really change a person’s quality of life.”

Optimal Therapeutics also produces Fematril, Viastat, Zalestra, Zyroxin, Neurovar, Immunitril and other revolutionary lifestyle products.

Optimal Therapeutics products can be purchased online at [www.BodEStore.com](http://www.BodEStore.com) or by way of Amazon.

News issued by: Optimal Therapeutics

# # #

Original Story ID: (188) :: 2005-03-0321-003

Original Keywords: Optimal Therapeutics, Urban Biologics, Camille Westhoff, Nextrutine, Fematril, Viastat, Zalestra, Zyroxin, Neurovar, Immunitril, Phosoplex, Bone & Joint, Joint Health, BioCell Collagen, Cox II, Cox II Inhibitors, Collagen, Healthy Joints, Joint Relief, Pain Relief, New Jersey Newswire, news Optimal Therapeutics